Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

This congress will be dedicated to improving the conduct of early anti-cancer clinical trials, bringing together those who are developing the most promising new cancer drugs and unveiling exciting new data.

ESMO TAT 2023

ESMO Targeted Anticancer Therapies Congress 2023
06–08 March 2023 | Paris, France

ESMO TAT 2023

ESMO Targeted Anticancer Therapies Congress 2023
06–08 March 2023 | Paris, France
This congress will be dedicated to improving the conduct of early anti-cancer clinical trials, bringing together those who are developing the most promising new cancer drugs and unveiling exciting new data.
Employing CRISPR technology to enhance tumor control and T-cell fitness 3:21
Employing CRISPR technology to enhance tumor control and T-cell fitness
Eliana Ruggiero • 9 Mar 2023
Limitations and solutions associated with CRISPR technology 4:16
Limitations and solutions associated with CRISPR technology
Eliana Ruggiero • 9 Mar 2023
Optimizing T-cell function in solid tumors using CRISPR and emerging tools 2:26
Optimizing T-cell function in solid tumors using CRISPR and emerging tools
Eliana Ruggiero • 9 Mar 2023
Highlights from ESMO TAT 2023 with Eliana Ruggiero 1:23
Highlights from ESMO TAT 2023 with Eliana Ruggiero
Eliana Ruggiero • 9 Mar 2023
RBN-2397 as a novel anticancer therapeutic 3:05
RBN-2397 as a novel anticancer therapeutic
Timothy Yap • 13 Mar 2023
SRK-181 as a novel latent TGFβ1 selective inhibitor 2:09
SRK-181 as a novel latent TGFβ1 selective inhibitor
Timothy Yap • 13 Mar 2023
JAVELIN PARP Medley: Combining PARP inhibitors and immune checkpoint inhibitors 2:14
JAVELIN PARP Medley: Combining PARP inhibitors and immune checkpoint inhibitors
Timothy Yap • 13 Mar 2023
Rapid evolution of early phase trial designs 1:03
Rapid evolution of early phase trial designs
Olga Solovyeva • 28 Feb 2023
Optimizing drug dosage in targeted therapies 2:56
Optimizing drug dosage in targeted therapies
Igor Vivanco • 6 Mar 2023
Challenges of performing neoantigen-specific TIL therapy 1:58
Challenges of performing neoantigen-specific TIL therapy
Elena Garralda Cabanas • 8 Mar 2023
Re-developed SPIRIT and CONSORT guidelines for early phase dose-finding trials 2:59
Re-developed SPIRIT and CONSORT guidelines for early phase dose-finding trials
Olga Solovyeva • 28 Feb 2023
Challenges of running clinical trials for glioblastoma 2:58
Challenges of running clinical trials for glioblastoma
Igor Vivanco • 6 Mar 2023
Highlights from ESMO TAT 2023 from Elena Garralda Cabanas 1:06
Highlights from ESMO TAT 2023 from Elena Garralda Cabanas
Elena Garralda Cabanas • 8 Mar 2023
Identifying neoantigen-specific T cells to increase the immunogenic response to TIL therapy 2:44
Identifying neoantigen-specific T cells to increase the immunogenic response to TIL therapy
Elena Garralda Cabanas • 8 Mar 2023
What impact will TILs play in the treatment landscape of melanoma? 1:46
What impact will TILs play in the treatment landscape of melanoma?
Elena Garralda Cabanas • 22 Mar 2023
Characterizing and targeting class II/III BRAF alterations 2:34
Characterizing and targeting class II/III BRAF alterations
Alison Schram • 3 Mar 2023
The content of VJOncology is intended for healthcare professionals